{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T15:15:16Z","timestamp":1771168516515,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,15]]},"DOI":"10.7759\/cureus.103654","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T14:57:38Z","timestamp":1771167458000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Conventional Versus Super-bioavailable Itraconazole in Dermatophytic Infections: A Prospective Randomized Comparative Study"],"prefix":"10.7759","author":[{"given":"Sakshi","family":"Sahni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Geetha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrita","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sana","family":"Islahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-023-00720-6","article-title":"Insights into changing dermatophyte spectrum in India through analysis of cumulative 161,245 cases between 1939 and 2021","volume":"188","author":"Kumar P","year":"2023","unstructured":"Kumar P, Ramachandran S, Das S, Bhattacharya SN, Taneja B. Insights into changing dermatophyte spectrum in India through analysis of cumulative 161,245 cases between 1939 and 2021. Mycopathologia. 2023, 188:183-202. 10.1007\/s11046-023-00720-6","journal-title":"Mycopathologia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.1545","article-title":"Tinea in the time before modern antifungal agents","volume":"153","author":"Jenkinson H","year":"2017","unstructured":"Jenkinson H, DiCicco B. Tinea in the time before modern antifungal agents. JAMA Dermatol. 2017, 153:543. 10.1001\/jamadermatol.2017.1545","journal-title":"JAMA Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_233_20","article-title":"Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) task force against recalcitrant Tinea (Itart) consensus on the management of glabrous Tinea (intact)","volume":"11","author":"Rengasamy M","year":"2020","unstructured":"Rengasamy M, Shenoy MM, Dogra S, et al.. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) task force against recalcitrant Tinea (Itart) consensus on the management of glabrous Tinea (intact). Indian Dermatol Online J. 2020, 11:502-19. 10.4103\/idoj.IDOJ_233_20","journal-title":"Indian Dermatol Online J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_137_17","article-title":"Is antifungal resistance a cause for treatment failure in dermatophytosis: a study focused on tinea corporis and cruris from a tertiary centre?","volume":"9","author":"Sardana K","year":"2018","unstructured":"Sardana K, Kaur R, Arora P, Goyal R, Ghunawat S. Is antifungal resistance a cause for treatment failure in dermatophytosis: a study focused on tinea corporis and cruris from a tertiary centre?. Indian Dermatol Online J. 2018, 9:90-5. 10.4103\/idoj.IDOJ_137_17","journal-title":"Indian Dermatol Online J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_618_20","article-title":"Super bioavailable itraconazole and its place and relevance in recalcitrant dermatophytosis: revisiting skin levels of itraconazole and minimum inhibitory concentration data","volume":"12","author":"Sardana K","year":"2021","unstructured":"Sardana K, Mathachan SR. Super bioavailable itraconazole and its place and relevance in recalcitrant dermatophytosis: revisiting skin levels of itraconazole and minimum inhibitory concentration data. Indian Dermatol Online J. 2021, 12:1-5. 10.4103\/idoj.IDOJ_618_20","journal-title":"Indian Dermatol Online J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00973-15","article-title":"Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states","volume":"59","author":"Abuhelwa AY","year":"2015","unstructured":"Abuhelwa AY, Foster DJ, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015, 59:5681-96. 10.1128\/AAC.00973-15","journal-title":"Antimicrob Agents Chemother"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S326642","article-title":"An open-label, randomized, double-arm clinical trial to compare the effectiveness and safety of super bioavailable itraconazole capsules and itraconazole capsules in the management of dermatophytosis in India","volume":"14","author":"Shenoy M","year":"2021","unstructured":"Shenoy M, Dhoot D, Mahajan H, Barkate H. An open-label, randomized, double-arm clinical trial to compare the effectiveness and safety of super bioavailable itraconazole capsules and itraconazole capsules in the management of dermatophytosis in India. Clin Cosmet Investig Dermatol. 2021, 14:1367-76. 10.2147\/CCID.S326642","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.25259\/IJDVL_301_20","article-title":"The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features","volume":"87","author":"Verma SB","year":"2021","unstructured":"Verma SB, Panda S, Nenoff P, et al.. The unprecedented epidemic-like scenario of dermatophytosis in India: I. Epidemiology, risk factors and clinical features. Indian J Dermatol Venereol Leprol. 2021, 87:154-75. 10.25259\/IJDVL_301_20","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4103\/ijph.ijph_987_22","article-title":"The epidemiological and mycological profile of superficial mycoses in India from 2015 to 2021: a systematic review","volume":"67","author":"Das S","year":"2023","unstructured":"Das S, Bandyopadhyay S, Sawant S, Chaudhuri S. The epidemiological and mycological profile of superficial mycoses in India from 2015 to 2021: a systematic review. Indian J Public Health. 2023, 67:123-35. 10.4103\/ijph.ijph_987_22","journal-title":"Indian J Public Health"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.4103\/jmms.jmms_2_24","article-title":"A study of sociodemographic profile and factors associated with dermatophytosis in tropical climates with comparison among treatment-naive and those who have abused topical corticosteroids\/combination","volume":"27","author":"Hemdani RM","year":"2025","unstructured":"Hemdani RM, Rajput GR, Chattejee M. A study of sociodemographic profile and factors associated with dermatophytosis in tropical climates with comparison among treatment-naive and those who have abused topical corticosteroids\/combination. J Mar Med Soc. 2025, 27:38-41. 10.4103\/jmms.jmms_2_24","journal-title":"J Mar Med Soc"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02522-17","article-title":"Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance","volume":"62","author":"Rudramurthy SM","year":"2018","unstructured":"Rudramurthy SM, Shankarnarayan SA, Dogra S, et al.. Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance. Antimicrob Agents Chemother. 2018, 62:02522-17. 10.1128\/AAC.02522-17","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20172212","article-title":"Dermatophytosis: clinical profile and association between socio-demographic factors and duration of infection","volume":"3","author":"Mahalakshmi R","year":"2017","unstructured":"Mahalakshmi R, Apoorva R, Joshua J. Dermatophytosis: clinical profile and association between socio-demographic factors and duration of infection. Int J Res Dermatol. 2017, 3:282-5. 10.18203\/issn.2455-4529.IntJResDermatol20172212","journal-title":"Int J Res Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.4103\/ijdvl.IJDVL_645_17","article-title":"A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India","volume":"84","author":"Pathania S","year":"2018","unstructured":"Pathania S, Rudramurthy SM, Narang T, Saikia UN, Dogra S. A prospective study of the epidemiological and clinical patterns of recurrent dermatophytosis at a tertiary care hospital in India. Indian J Dermatol Venereol Leprol. 2018, 84:678-84. 10.4103\/ijdvl.IJDVL_645_17","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.22207\/JPAM.17.3.42","article-title":"Comparison of efficacy and safety between super\u2011bioavailable itraconazole and conventional itraconazole in the treatment of tinea infection of glabrous skin - a randomised observer\u2011blinded pilot study","volume":"17","author":"Mohapatra L","year":"2023","unstructured":"Mohapatra L, Dixit N, Agrawal I, Kar BR, Singh BS. Comparison of efficacy and safety between super\u2011bioavailable itraconazole and conventional itraconazole in the treatment of tinea infection of glabrous skin - a randomised observer\u2011blinded pilot study. J Pure Appl Microbiol. 2023, 17:1776-82. 10.22207\/JPAM.17.3.42","journal-title":"J Pure Appl Microbiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20211427","article-title":"Comparative clinical effectiveness and safety of super bioavailable itraconazole and conventional itraconazole in management of dermatophytosis: a retrospective data analysis","volume":"7","author":"Mahajan H","year":"2021","unstructured":"Mahajan H, Dhoot D, Deshmukh G, Barkate H. Comparative clinical effectiveness and safety of super bioavailable itraconazole and conventional itraconazole in management of dermatophytosis: a retrospective data analysis. Int J Res Dermatol. 2021, 7:388-94. 10.18203\/issn.2455-4529.IntJResDermatol20211427","journal-title":"Int J Res Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S421583","article-title":"Efficacy of super-bioavailable itraconazole and conventional itraconazole at different dosing regimens in glabrous tinea infection - a randomized clinical trial","volume":"17","author":"Shenoy MM","year":"2023","unstructured":"Shenoy MM, De A, Shah B, et al.. Efficacy of super-bioavailable itraconazole and conventional itraconazole at different dosing regimens in glabrous tinea infection - a randomized clinical trial. Drug Des Devel Ther. 2023, 17:2899-908. 10.2147\/DDDT.S421583","journal-title":"Drug Des Devel Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijced.2021.024","article-title":"Clinical assessment of super bioavailable itraconazole 50 mg in dermatophytosis (clear 50)","volume":"7","author":"Ghate S","year":"2021","unstructured":"Ghate S, Dhoot D, Mahajan H, Barkate H. Clinical assessment of super bioavailable itraconazole 50 mg in dermatophytosis (clear 50). Indian J Clin Exp Dermatol. 2021, 7:125-9. 10.18231\/j.ijced.2021.024","journal-title":"Indian J Clin Exp Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.3745","article-title":"Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea corporis\/cruris: a randomized clinical trial","volume":"158","author":"Khurana A","year":"2022","unstructured":"Khurana A, Agarwal A, Agrawal D, et al.. Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea corporis\/cruris: a randomized clinical trial. JAMA Dermatol. 2022, 158:1269-78. 10.1001\/jamadermatol.2022.3745","journal-title":"JAMA Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00400-20","article-title":"Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-day steady-state administration of Suba-itraconazole and conventional itraconazole capsules in healthy adults","volume":"64","author":"Thompson GR 3rd","year":"2020","unstructured":"Thompson GR 3rd, Lewis P, Mudge S, Patterson TF, Burnett BP. Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-day steady-state administration of Suba-itraconazole and conventional itraconazole capsules in healthy adults. Antimicrob Agents Chemother. 2020, 64:00400-20. 10.1128\/AAC.00400-20","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/458390-efficacy-and-safety-of-conventional-versus-super-bioavailable-itraconazole-in-dermatophytic-infections-a-prospective-randomized-comparative-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T14:57:39Z","timestamp":1771167459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/458390-efficacy-and-safety-of-conventional-versus-super-bioavailable-itraconazole-in-dermatophytic-infections-a-prospective-randomized-comparative-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.103654","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}